Acute myocarditis after administration of BNT162b2 vaccine against COVID-19

Juan F. Cueva-Recalde, Department of Cardiology, Hospital Clínico Universitario Lozano Blesa; Research Group GIISA-003, Instituto de Investigación Sanitaria Aragón; Spain
David Ibáñez-Muñoz, Department of Radiology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Daniel Meseguer-González, Department of Cardiology, Hospital Clínico Universitario Lozano Blesa; Research Group GIISA-003, Instituto de Investigación Sanitaria Aragón; Spain
Teresa Sola-Moreno, Department of Cardiology, Hospital Clínico Universitario Lozano Blesa, Spain
Nerea Yanguas-Barea, Research Group GIISA-003, Instituto de Investigación Sanitaria Aragón, Spain
José R. Ruiz-Arroyo, Department of Cardiology, Hospital Clínico Universitario Lozano Blesa; Research Group GIISA-003, Instituto de Investigación Sanitaria Aragón; Spain

COVID-19 mRNA vaccines have been associated with the development of myocarditis, specifically in young men after the administration of the second dose, with a low rate of 1 case/10 000 vaccinated people¹.